Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia

Current Pharmaceutical Biotechnology

Volumn 12, Issue 3, 2011, Pages 437-448

  Kucinski, Aaron J ^a   Stachowiak, Michal K ^a   Wersinger, Scott R ^b   Lippiello, Patrick M ^c   Bencherif, Merouane ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c TARGACEPT INC   (United States)

Author keywords

Acetylcholine; Alpha7; Cholinergic; Cognition; Nicotinic receptors; Schizophrenia

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; A 582941; CLOZAPINE; DOPAMINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; N (1 AZABICYCLO[3.2.1]OCT 3 YL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; NEURONAL NICOTINIC RECEPTOR ALPHA7; NICOTINIC RECEPTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

AKATHISIA; ARTICLE; ATTENTION; CHROMOSOME 15; COGNITION; COGNITIVE DEFECT; DELUSION; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG TARGETING; EVOKED AUDITORY RESPONSE; GABAERGIC SYSTEM; HALLUCINATION; HUMAN; NEGATIVE SYNDROME; NEUROANATOMY; NEUROMODULATION; NONHUMAN; PARKINSONISM; POSITIVE SYNDROME; PROMOTER REGION; PROTEIN EXPRESSION; SCHIZOPHRENIA; SENSORY GATING; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; TARDIVE DYSKINESIA; WORKING MEMORY;

AFFECTIVE SYMPTOMS; ANIMALS; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; NICOTINIC AGONISTS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, NICOTINIC; SCHIZOPHRENIA;

ANIMALIA; MAMMALIA;

EID: 79551673655     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794480589     Document Type: Article

References (152)

1. Carlsson, A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry, 2006, 39 (Suppl 1), S10-S14.
2. Carlsson, A.; Waters, N.; Holm-Waters, S.; Tedroff, J.; Nilsson, M.; Carlsson, M. L. Interactions between monoamines, glutamate, and GABA in schizophrenia, new evidence. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 237-260.
3. Money, T.T.; Scarr, E.; Udawela, M.; Gibbons, A.S.; Jeon, W. J.; Seo, M. S.; Dean, B. Treating Schizophrenia, Novel Targets for the Cholinergic System. CNS Neurol. Disord. Drug Targets, 2009, 9(2), 241-256.
4. Goldman-Rakic, P. S.; Muly, E. C III.; Williams, G.V. D(1) receptors in prefrontal cells and circuits. Brain Res. Brain Res. Rev., 2000, 31, 295-301.
5. Wong, A. H.; Van Tol, H. H. Schizophrenia, from phenomenology to neurobiology. Neurosci. Biobehav. Rev., 2003, 27, 269-306.
6. Harrison, P. J. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors. Br. J. Psychiatry Suppl., 1999, 38, 12-22.
7. Harrison, P. J. Dopamine and schizophrenia--proof at last? Lancet, 2000, 356, 958-959.
8. Toru, M. [Schizophrenia as a dopamine excess syndrome]. Nippon Rinsho, 1983, 41,1021-1027.
9. bi-Dargham, A.; Gil, R.; Krystal, J.; Baldwin, R. M.; Seibyl, J. P.; Bowers, M.; van Dyck, C. H.; Charney, D. S.; Innis, R. B.; Laru-elle, M. Increased striatal dopamine transmission in schizophrenia, confirmation in a second cohort. Am. J. Psychiatry, 1998, 155, 761-767.
10. Kugaya, A.; Fujita, M.; Innis, R. B. Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Ann. Nucl. Med., 2000, 14,1-9.
11. Meyer-Lindenberg, A.; Miletich, R.S.; Kohn, P. D.; Esposito, G.; Carson, R. E.; Quarantelli, M.; Weinberger, D. R.; Berman, K. F. Reduced prefrontal activity predicts exaggerated striatal dopa- minergic function in schizophrenia. Nat. Neurosci., 2002, 5, 267-271.
12. Barnes, T.; Drake, R. Pharmacological strategies for relapse prevention in schizophrenia. Psychiatry, (England) 2007, 6, 351-356.
13. Holden, C. Psychiatric drugs. Excited by glutamate. Science, 2003, 300,1866-1868.
14. Holden, C. Neuroscience. Deconstructing schizophrenia. Science, 2003, 299,333-335.
15. Sagud, M.; Mihaljevic-Peles, A.; Muck-Seler, D.; Pivac, N.; Vuk-san-Cusa, B.; Brataljenovic, T.; Jakovljevic, M. Smoking and schizophrenia. Psychiatr. Danub., 2009, 21, 371-375.
16. Esterberg, M. L.; Compton, M. T. Smoking behavior in persons with a schizophrenia-spectrum disorder, a qualitative investigation of the transtheoretical model. Soc. Sci. Med., 2005, 61, 293-303.
17. DeLuca, V.; Wong, A. H.; Muller, D. J.; Wong, G. W.; Tyndale, R. F.; Kennedy, J. L. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology, 2004, 29,1522-1526.
18. Avila, M. T.; Sherr, J. D.; Hong, E.; Myers, C. S.; Thaker, G. K. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology, 2003, 28, 2184-2191.
19. Harris, J. G.; Kongs, S.; Allensworth, D.; Martin, L.; Tregellas, J.; Sullivan, B.; Zerbe, G.; Freedman, R. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology, 2004, 29,1378-1385.
20. Levin, E. D.; Wilson, W.; Rose, J. E.; McEvoy, J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology, 1996, 15, 429-436.
21. Bidzan, L. A review of the effects of nicotine on schizophrenia. Psychiatr. Pol., 2007, 41, 737-744.
22. Taly, A.; Corringer, P. J.; Guedin, D.; Lestage, P.; Changeux, J. P. Nicotinic receptors, allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov., 2009, 8, 733-750.
23. Radek, R. J.; Kohlhaas, K.L.; Rueter, L. E.; Mohler, E. G. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr. Pharm. Des., 2010, 16, 309-322.
24. Buchanan, R. W.; Freedman, R.; Javitt, D. C.; bi-Dargham, A.; Lieberman, J. A. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr. Bull., 2007, 33,1120-1130.
25. Paterson, D.; Nordberg, A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol., 2000, 61, 75-111.
26. Martin, L. F.; Freedman, R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int. Rev. Neurobiol., 2007, 78, 225-246.
27. Freedman, R.; Adams, C. E.; Leonard, S. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneu-rons in schizophrenia. J. Chem. Neuroanat., 2000, 20, 299-306.
28. Guan, Z. Z.; Zhang, X.; Blennow, K.; Nordberg, A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport, 1999, 10, 1779-1782.
29. Livingstone, P. D.; Dickinson, J. A.; Srinivasan, J.; Kew, J. N.; Wonnacott, S. Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596. J. Mol. Neurosci., 2010, 40,172-176.
30. Livingstone, P. D.; Wonnacott, S. Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem. Pharmacol., 2009, 78, 744-755.
31. Livingstone, P. D.; Srinivasan, J.; Kew, J. N.; Dawson, L. A.; Gotti, C.; Moretti, M.; Shoaib, M.; Wonnacott, S. alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur. J. Neurosci., 2009, 29,539-550.
32. Carlsson, A.; Waters, N.; Carlsson, M. L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur. Arch. Psychiatry. Clin. Neurosci., 1999, 249 (Suppl 4), 37-43.
33. Freedman, R. Schizophrenia. N. Engl. J. Med., 2003, 349, 1738-1749.
34. Poorthuis, R. B.; Goriounova, N. A.; Couey, J. J.; Mansvelder, H. D. Nicotinic actions on neuronal networks for cognition, general principles and long-term consequences. Biochem. Pharmacol., 2009, 78, 668-676.
35. Bogerts, B.; Hantsch, J.; Herzer, M. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. Biol. Psychiatry., 1983, 18, 951-969.
36. Bogerts, B.; Lieberman, J. A.; Bilder, R. M.; Ashtari, M.; Degreef, G.; Lerner, G.; Johns, C.; Masiar, S. A volumetric MRI study of limbic structures in chronic schizophrenia--relationship to psycho-pathology. Clin. Neuropharmacol., 1992, 15 (Suppl 1) Pt A, 112A-113A.
37. Lewis, D. A. Neural circuitry of the prefrontal cortex in schizophrenia. Arch. Gen. Psychiatry., 1995, 52, 269-273.
38. Lewis, D. A.; Gonzalez-Burgos, G. Intrinsic excitatory connections in the prefrontal cortex and the pathophysiology of schizophrenia. Brain Res. Bull., 2000, 52, 309-317.
39. Marek, G. J.; Behl, B.; Bespalov, A.Y.; Gross, G.; Lee, Y.; Schoe-maker, H. Glutamatergic (N-methyl-D-aspartate receptor) hy-pofrontality in schizophrenia, too little juice or a miswired brain? Mol. Pharmacol., 2010, 77, 317-326.
40. Laruelle, M.; Kegeles, L.S.; bi-Dargham, A. Glutamate, dopamine, and schizophrenia, from pathophysiology to treatment. Ann. N Y. Acad. Sci., 2003, 1003,138-158.
41. Marek, G. J. Serotonin and dopamine interactions in rodents and primates, implications for psychosis and antipsychotic drug development. Int. Rev. Neurobiol., 2007, 78, 165-192.
42. Dani, J. A.; Bertrand, D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol., 2007, 47,699-729.
43. Behrendt, R. P. Dysregulation of thalamic sensory transmission in schizophrenia, neurochemical vulnerability to hallucinations. J. Psychopharmacol., 2006, 20,356-372.
44. Dickinson, J. A.; Kew, J. N.; Wonnacott, S. Presynaptic alpha 7-and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol. Pharmacol., 2008, 74, 348-359.
45. Arnaiz-Cot, J. J.; Gonzalez, J. C.; Sobrado, M.; Baldelli, P.; Car-bone, E.; Gandia, L.; Garcia, A.G.; Hernandez-Guijo, J. M. Allos-teric modulation of alpha 7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmission. Eur. J. Neurosci., 2008, 27, 1097-1110.
46. Quarta, D. Naylor, C. G.; Barik, J.; Fernandes, C.; Wonnacott, S.; Stolerman, I. P. Drug discrimination and neurochemical studies in alpha7 null mutant mice, tests for the role of nicotinic alpha7 receptors in dopamine release. Psychopharmacology, (Berl) 2009, 203(2), 399-410.
47. Bitner, R. S.; Bunnelle, W. H.; Anderson, D. J.; Briggs, C. A.; Buccafusco, J.; Curzon, P.; Decker, M.W.; Frost, J. M.; Gronlien, J. H.; Gubbins, E.; Li, J.; Malysz, J.; Markosyan, S.; Marsh, K.; Meyer, M. D.; Nikkel, A. L.; Radek, R. J.; Robb, H. M.; Timmer-mann, D.; Sullivan, J. P.; Gopalakrishnan, M. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J. Neurosci., 2007, 27,10578-10587.
48. Mansvelder, H. D.; McGehee, D. S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron, 2000, 27, 349-357.
49. Liu, Q.; Zhang, J.; Zhu, H.; Qin, C.; Chen, Q.; Zhao, B. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J., 2007, 21, 61-73.
50. Kwon, J. S.; O'Donnell, B. F.; Wallenstein, G. V.; Greene, R.W.; Hirayasu, Y.; Nestor, P. G.; Hasselmo, M. E.; Potts, G. F.; Shenton, M. E.; McCarley, R. W. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch. Gen. Psychiatry, 1999, 56,1001-1005.
51. Quik, M.; Polonskaya, Y.; Gillespie, A.; Jakowec, M.; Lloyd, G. K.; Langston, J. W. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. J. Comp. Neurol., 2000, 425, 58-69.
52. Lena, C.; Changeux, J. P. Role of Ca2+ ions in nicotinic facilitation of GABA release in mouse thalamus. J. Neurosci., 1997, 17, 576-585.
53. Waldo, M. C.; Cawthra, E.; Adler, L. E.; Dubester, S.; Staunton, M.; Nagamoto, H.; Baker, N.; Madison, A.; Simon, J.; Scherzinger, A. Auditory sensory gating, hippocampal volume, and catechola-mine metabolism in schizophrenics and their siblings. Schizophr. Res., 1994, 12, 93-106.
54. Sydserff, S.; Sutton, E. J.; Song, D.; Quirk, M. C.; Maciag, C.; Li, C.; Jonak, G.; Gurley, D.; Gordon, J. C.; Christian, E. P.; Doherty, J. J.; Hudzik, T.; Johnson, E.; Mrzljak, L.; Piser, T.; Smagin, G. N.; Wang, Y.; Widzowski, D.; Smith, J. S. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem. Pharmacol., 2009, 78, 880-888.
55. Pichat, P.; Bergis, O. E.; Terranova, J. P.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C.; Steinberg, R.; Stemmelin, J.; Oury-Donat, F.; Avenet, P.; Griebel, G.; Scatton, B. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist, (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology, 2007, 32, 17-34.
56. van Haaren, F.; Anderson, K.G., Haworth, S.C.; Kem, W.R. GTS-21, a mixed nicotinic receptor agonist/antagonist, does not affect the nicotine cue. Pharmacol. Biochem. Behav., 1999, 64(2), 439-444.
57. Azam, L.; Winzer-Serhan, U. H.; Chen, Y.; Leslie, F. M. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. J. Comp. Neurol., 2002, 444, 260-274.
58. Grottick, A. J.; Trube, G., Corrigall, W.A.; Huwyler, J.; Malherbe, P.; Wyler, R.; Higgins, G.A. Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J. Pharmacol. Exp. Ther., 2000, 294(3), 1112-1119.
59. Mameli-Engvall, M.; Evrard, A.; Pons, S.; Maskos, U.; Svens-son, T.H.; Changeux, J. P.; Faure, P. Hierarchical control of dopa-mine neuron-firing patterns by nicotinic receptors. Neuron, 2006, 50, 911-921.
60. Kempsill, F.E.; Pratt, J.A. Mecamylamine but not the alpha7 receptor antagonist alpha-bungarotoxin blocks sensitiza-tion to the locomotor stimulant effects of nicotine. Br. J. Pharmacol., 2000, 131(5), 997-1003.
61. Fang, X.; Stachowiak, E. K.; Dunham-Ems, S. M.; Klejbor, I.; Stachowiak, M. K. Control of CREB-binding protein signaling by nuclear fibroblast growth factor receptor-1, a novel mechanism of gene regulation. J. Biol. Chem., 2005, 280, 28451-28462.
62. Jones, E. G.; Tighilet, B.; Tran, B. V.; Huntsman, M. M. Nucleus-and cell-specific expression of NMDA and non-NMDA receptor subunits in monkey thalamus. J. Comp. Neurol., 1998, 397, 371-393.
63. Hajos, M.; Hurst, R. S.; Hoffmann, W. E.; Krause, M.; Wall, T.M.; Higdon, N. R.; Groppi, V. E. The selective alpha7 nicotinic acetyl-choline receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo [2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther., 2005, 312,1213-1222.
64. Carlsson, A.; Waters, N.; Carlsson, M. L. Neurotransmitter interactions in schizophrenia--therapeutic implications. Biol. Psychiatry, 1999, 46,1388-1395.
65. Marchi, M.; Risso, F.; Viola, C.; Cavazzani, P.; Raiteri, M. Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J. Neurochem., 2002, 80,1071-1078.
66. Toth, E.; Sershen, H.; Hashim, A.; Vizi, E. S.; Lajtha, A. Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions, role of glutamic acid. Neu-rochem. Res., 1992, 17, 265-271.
67. Levin, E. D.; Simon, B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology, (Berl) 1998, 138, 217-230.
68. Grace, A. A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity, a hypothesis for the etiology of schizophrenia. Neuroscience, 1991, 41,1-24.
69. West, A. R.; Grace, A.A. The role of frontal-subcortical circuits in the pathophysiology of schizophrenia., Lichter, D. G.; Cummings, J. L., Eds.; In: Frontal-Subcortical Circuits in Psychiatric and Neurological Disorders; Guilford Publications, New York, NY, 2001, pp. 372-400.
70. Balla, A.; Koneru, R.; Smiley, J.; Sershen, H.; Javitt, D. C. Continuous phencyclidine treatment induces schizophrenia-like hyper-reactivity of striatal dopamine release. Neuropsychopharmacology, 2001, 25,157-164.
71. Kegeles, L. S.; bi-Dargham, A.; Zea-Ponce, Y.; Rodenhiser-Hill, J.; Mann, J. J.; Van Heertum, R. L.; Cooper, T. B.; Carlsson, A.; La-ruelle, M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans, implications for schizophrenia. Biol. Psychiatry, 2000, 48, 627-640.
72. Thompson, J. L.; Pogue-Geile, M. F.; Grace, A.A. Developmental pathology, dopamine, and stress, a model for the age of onset of schizophrenia symptoms. Schizophr. Bull., 2004, 30, 875-900.
73. Grace, A. A.; Bunney, B. S.; Moore, H.; Todd, C. L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci., 1997, 20, 31-37.
74. Matsuyama, S.; Matsumoto, A.; Enomoto, T.; Nishizaki, T. Activation of nicotinic acetylcholine receptors induces long-term poten-tiation in vivo in the intact mouse dentate gyrus. Eur. J. Neurosci., 2000, 12, 3741-3747.
75. Alkondon, M.; Pereira, E. F.; Barbosa, C. T.; Albuquerque, E. X. Neuronal nicotinic acetylcholine receptor activation modulates gamma-aminobutyric acid release from CA1 neurons of rat hippo-campal slices. J. Pharmacol. Exp. Ther., 1997, 283,1396-1411.
76. Stevens, K. E.; Kem, W. R.; Mahnir, V. M.; Freedman, R. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology, 1998, (Berl) 136, 320-327.
77. Carlezon, W. A Jr.; Duman, R. S.; Nestlerm E, J. The many faces of CREB. Trends Neurosci., 2005, 28, 436-445.
78. Klejbor, I.; Myers, J. M.; Hausknecht, K.; Corso, T. D.; Gambino, A. S.; Morys, J.; Maher, P. A.; Hard, R.; Richards, J.; Stachowiak, E. K.; Stachowiak, M. K. Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice. J. Neurochem., 2006, 97,1243-1258.
79. Gaughran, F.; Payne, J.; Sedgwick, P. M.; Cotter, D.; Berry, M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res. Bull., 2006, 70, 221-227.
80. Riva, M. A.; Molteni, R.; Tascedda, F.; Massironi, A.; Racagni, G. Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine. Neuropharmacology, 1999, 38,1075-1082.
81. O'Donovan, M. C.; Craddock, N.; Norton, N.; Williams, H.; Peirce, T.; Moskvina, V.; Nikolov, I.; Hamshere, M.; Carroll, L.; Geor-gieva, L.; Dwyer, S.; Holmans, P.; Marchini, J. L.; Spencer, C. C.; Howie, B.; Leung, H. T.; Hartmann, A. M.; Moller, H. J.; Morris, D. W.; Shi, Y; Feng, G.; Hoffmann, P.; Propping, P.; Vasilescu, C.; Maier, W.; Rietschel, M.; Zammit, S.; Schumacher, J.; Quinn, E. M.; Schulze, T. G.; Williams, N. M.; Giegling, I.; Iwata, N.; Ikeda, M.; Darvasi, A.; Shifman, S.; He, L.; Duan, J.; Sanders, A. R.; Levinson, D. F.; Gejman, P. V.; Gejman, P. V.; Sanders, A. R.; Duan, J.; Levinson, D. F.; Buccola, N.G.; Mowry, B. J.; Freedman, R.; Amin, F.; Black, D. W.; Silverman, J. M.; Byerley, W. F.; Cloninger, C. R.; Cichon, S.; Nothen, M. M.; Gill, M.; Corvin, A.; Rujescu, D.; Kirov, G.; Owen, M. J. Identification of loci associated with schizophrenia by genome-wide association and follow- up. Nat Genet., 2008, 40(9)1053-1055.
82. O'Donovan, M. C.; Norton, N.; Williams, H.; Peirce, T.; Moskvina, V.; Nikolov, I.; Hamshere, M.; Carroll, L.; Georgieva, L.; Dwyer, S.; Holmans, P.; Marchini, J. L.; Spencer, C. C.; Howie, B.; Leung, H. T.; Giegling, I.; Hartmann, A. M.; Moller, H. J.; Morris, D. W.; Shi, Y.; Feng, G.; Hoffmann, P.; Propping, P.; Vasilescu, C.; Maier, W.; Rietschel, M.; Zammit, S.; Schumacher, J.; Quinn, E. M.; Schulze, T. G.; Iwata, N.; Ikeda, M.; Darvasi, A.; Shifman, S.; He, L.; Duan, J.; Sanders, A. R.; Levinson, D. F.; Adolfsson, R.; Osby, U.; Terenius, L.; Jonsson, E. G.; Cichon, S.; Nothen, M. M.; Gill, M.; Corvin, A. P.; Rujescu, D.; Gejman, P. V.; Kirov, G.; Craddock, N.; Williams, N. M.; Owen, M. J. Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking fibroblast growth factor receptor 2. Mol. Psychiatry, 2009, 14, 30-36.
83. Trokovic, R.; Jukkola, T.; Saarimaki, J.; Peltopuro, P.; Naserke, T.; Weisenhorn, D. M.; Trokovic, N.; Wurst, W.; Partanen, J. Fgfr1-dependent boundary cells between developing mid- and hindbrain. Dev. Biol., 2005, 278, 428-439.
84. Trokovic, R.; Trokovic, N.; Hernesniemi, S.; Pirvola, U.; Vogt Weisenhorn, D. M.; Rossant, J.; McMahon, A. P.; Wurst, W.; Partanen, J. FGFR1 is independently required in both developing mid-and hindbrain for sustained response to isthmic signals. EMBO J., 2003, 22,1811-1823.
85. Blak, A. A.; Naserke, T.; Saarimaki-Vire, J.; Peltopuro, P.; Gi-raldo-Velasquez, M.; Vogt Weisenhorn, D. M.; Prakash, N.; Sendtner, M.; Partanen, J.; Wurst, W. Fgfr2 and Fgfr3 are not required for patterning and maintenance of the midbrain and anterior hindbrain. Dev. Biol., 2007, 303, 231-243.
86. Stachowiak, E. K.; Roy, I.; Lee, Y. W.; Capacchietti, M.; Aletta, J. M.; Prasad, P. N.; Stachowiak, M. K. Targeting novel integrative nuclear FGFR1 signaling by nanoparticle-mediated gene transfer stimulates neurogenesis in the adult brain. Integr. Biol., (Camb.) 2009, 1, 394-403.
87. Belluardo, N.; Mudo, G.; Blum, M.; Amato, G.; Fuxe, K. Neu-rotrophic effects of central nicotinic receptor activation. J. Neural. Transm. Suppl., 2000, 60, 227-245.
88. Belluardo, N.; Mudo, G.; Blum, M.; Fuxe, K. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav. Brain Res., 2000, 113, 21-34.
89. Belluardo, N.; Mudo', G.; Bonomo, A.; Di, L. V.; Frinchi, M.; Fuxe, K. Nicotine-induced fibroblast growth factor-2 restores the age-related decline of precursor cell proliferation in the subven-tricular zone of rat brain. Brain Res., 2008, 1193, 12-24.
90. Mudo, G.; Belluardo, N.; Mauro, A.; Fuxe, K. Acute intermittent nicotine treatment induces fibroblast growth factor-2 in the sub ventricular zone of the adult rat brain and enhances neuronal precursor cell proliferation. Neuroscience, 2007, 145, 470-483.
91. Garrido, R.; Springer, J. E.; Hennig, B.; Toborek, M. Apoptosis of spinal cord neurons by preventing depletion nicotine attenuates arachidonic acid-induced of neurotrophic factors. J. Neurotrauma, 2003, 20,1201-1213.
92. Son, J. H.; Winzer-Serhan, U. H. Chronic neonatal nicotine exposure increases mRNA expression of neurotrophic factors in the postnatal rat hippocampus. Brain Res., 2009, 1278, 1-14.
93. Ng, M. K.; Wu, J.; Chang, E.; Wang, B.Y.; Katzenberg-Clark, R.; Ishii-Watabe, A.; Cooke, J. P. A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration. Arterioscler Thromb. Vasc. Biol., 2007, 27, 106-112.
94. Carpenter, W. T.; Koenig, J. I. The evolution of drug development in schizophrenia, past issues and future opportunities. Neuropsy-chopharmacology, 2008, 33, 2061-2079.
95. Adler, L. E.; Olincy, A.; Waldo, M.; Harris, J. G.; Griffith, J.; Stevens, K.; Flach, K.; Nagamoto, H.; Bickford, P.; Leonard, S.; Freedman, R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull., 1998, 24,189-202.
96. Venables, P. H. Hippocampal function and schizophrenia. Experimental psychological evidence. Ann. N Y. Acad. Sci., 1992, 658,111-127.
97. Clementz, B. A.; Geyer, M. A.; Braff, D. L. Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am. J. Psychiatry, 1998, 155,1691-1694.
98. Freedman, R.; Leonard, S.; Gault, J. M.; Hopkins, J.; Cloninger, C. R.; Kaufmann, C. A.; Tsuang, M. T.; Farone, S. V.; Malaspina, D.; Svrakic, D. M.; Sanders, A.; Gejman, P. Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am. J. Med. Genet., 2001, 105, 20-22.
99. Adler, L. E.; Hoffer, L. D.; Wiser, A.; Freedman, R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry, 1993, 150, 1856-1861.
100. Adler, L. E.; Hoffer, L. J.; Griffith, J.; Waldo, M. C.; Freedman, R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry, 1992, 32, 607-616.
101. Freedman, R.; Adler, L. E.; Bickford, P.; Byerley, W.; Coon, H.; Cullum, C. M.; Griffith, J. M.; Harris, J. G.; Leonard, S.; Miller, C. Schizophrenia and nicotinic receptors. Harv. Rev. Psychiatry., 1994, 2, 179-192.
102. Luntz-Leybman, V.; Bickford, P. C.; Freedman, R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res., 1992, 587, 130-136.
103. Simosky, J. K.; Stevens, K. E.; Adler, L. E.; Freedman, R. Clozap-ine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl), 2003, 165, 386-396.
104. Ralph, R. J.; Paulus, M. P.; Fumagalli, F.; Caron, M. G.; Geyer, M.A. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice, differential effects of D1 and D2 receptor antagonists. J. Neurosci., 2001, 21, 305-313.
105. Geyer, M. A.; Krebs-Thomson, K.; Braff, D. L.; Swerdlow, N. R. Pharmacological studies of prepulse inhibition models of sensori-motor gating deficits in schizophrenia, a decade in review. Psycho-pharmacology (Berl), 2001, 156, 117-154.
106. Hauser, T. A.; Kucinski, A.; Jordan, K. G.; Gatto, G. J.; Wersinger, S. R.; Hesse, R. A.; Stachowiak, E. K.; Stachowiak, M. K.; Papke, R. L.; Lippiello, P. M.; Bencherif, M. TC-5619, an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol., 2009, 78, 803-812.
107. Klejbor, I.; Kucinski, A.; Wersinger, S. R.; Corso, T.; Spodnik, J. H.; Dziewiatkowski, J.; Morys, J.; Hesse, R. A.; Rice, K. C.; Mi-letich, R.; Stachowiak, E. K.; Stachowiak, M. K. Serotonergic hy-perinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis. Schizophr. Res., 2009, 113, 308-321.
108. Sams-Dodd, F. Phencyclidine in the social interaction test, an animal model of schizophrenia with face and predictive validity. Rev. Neurosci., 1999, 10, 59-90.
109. Hoyle, E.; Genn, R. F.; Fernandes, C.; Stolerman, I. P. Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl), 2006, 189, 211-223.
110. Young, J. W.; Crawford, N.; Kelly, J. S.; Kerr, L.E.; Marston, H. M.; Spratt, C.; Finlayson, K.; Sharkey, J. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur. Neuropsychopharmacol., 2007, 17,145-155.
111. Stolerman, I.P.; Chamberlain, S.; Bizarro, L.; Fernandes, C.; Schalkwyk, L. The role of nicotinic receptor alpha 7 subunits in nicotine discrimination. Neuropharmacology, 2004, 46, 363-371.
112. Keller, J. J.; Keller, A. B.; Bowers, B. J.; Wehner, J. M. Performance of alpha7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task. Behav. Brain Res., 2005, 162,143-152.
113. Fernandes, C.; Hoyle, E.; Dempster, E.; Schalkwyk, L.C.; Collier, D.A. Performance deficit of alpha7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory. Genes Brain Behav., 2006, 5, 433-440.
114. Leiser, S. C.; Bowlby, M. R.; Comery, T. A.; Dunlop, J. A cog in cognition, how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol. Ther., 2009, 122, 302-311.
115. Arendash, G. W.; Sengstock, G. J.; Sanberg, P. R.; Kem, W. R. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res., 1995, 674, 252-259.
116. Meyer, E. M.; Tay, E. T.; Papke, R. L.; Meyers, C.; Huang, G. L.; De Fiebre, C. M. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res., 1997, 768, 49-56.
117. Tietje, K. R.; Anderson, D. J.; Bitner, R. S.; Blomme, E. A.; Brackemeyer, P. J.; Briggs, C. A.; Browman, K. E.; Bury, D.; Cur-zon, P.; Drescher, K. U.; Frost, J. M.; Fryer, R. M.; Fox, G. B.; Gronlien, J. H.; Hakerud, M.; Gubbins, E. J.; Halm, S.; Harris, R.; Helfrich, R. J.; Kohlhaas, K. L.; Law, D.; Malysz, J.; Marsh, K. C.; Martin, R. L.; Meyer, M. D.; Molesky, A. L.; Nikkel, A. L.; Otte, S.; Pan, L.; Puttfarcken, P. S.; Radek, R. J.; Robb, H. M.; Spies, E.; Thorin-Hagene, K.; Waring, J. F.; Ween, H.; Xu, H.; Gopalakrish-nan, M.; Bunnelle, W. H. Preclinical characterization of A-582941, a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci. Ther., 2008, 14, 65-82.
118. Briggs, C. A.; Anderson, D. J.; Brioni, J. D.; Buccafusco, J. J.; Buckley, M. J.; Campbell, J. E.; Decker, M. W.; Donnelly-Roberts, D.; Elliott, R. L.; Gopalakrishnan, M.; Holladay, M. W.; Hui, Y. H.; Jackson, W. J.; Kim, D. J.; Marsh, K. C.; O'Neill, A.; Prender-gast, M. A.; Ryther, K. B.; Sullivan, J. P.; Arneric, S. P., Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav., 1997, 57, 231-241.
119. Buccafusco, J. J.; Terry, A. V Jr.; Decker, M. W.; Gopalakrishnan, M. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem. Pharmacol., 2007, 74, 1202-1211.
120. Boess, F. G.; De, V. J.; Erb, C.; Flessner, T.; Hendrix, M.; Luithle, J.; Methfessel, C.; Riedl, B.; Schnizler, K.; van der Staay, F. J.; Van, K. M.; Wiese, W. B.; Koenig, G. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2- carboxamide improves working and recognition memory in rodents. J. Pharmacol. Exp. Ther., 2007, 321, 716-725.
121. Chan, W. K.; Wong, P.T.; Sheu, F. S. Frontal cortical alpha7 and alpha4beta2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacology, 2007, 52,1641-1649.
122. Van, K.M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology (Berl), 2004, 172, 375-383.
123. Roncarati, R.; Scali, C.; Comery, T. A.; Grauer, S. M.; Aschmi, S.; Bothmann, H.; Jow, B.; Kowal, D.; Gianfriddo, M.; Kelley, C.; Zanelli, U.; Ghiron, C.; Haydar, S.; Dunlop, J.; Terstappen, G. C. Procognitive and neuroprotective activity of a novel alpha7 nico-tinic acetylcholine receptor agonist for treatment of neurodegenera-tive and cognitive disorders. J. Pharmacol. Exp. Ther., 2009, 329, 459-468.
124. Sydserff, S.; Sutton, E. J.; Song, D.; Quirk, M. C.; Maciag, C.; Li, C.; Jonak, G.; Gurley, D.; Gordon, J. C.; Christian, E. P.; Doherty, J. J.; Hudzik, T.; Johnson, E.; Mrzljak, L.; Piser, T.; Smagin, G. N.; Wang, Y.; Widzowski, D.; Smith, J. S. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem. Pharmacol., 2009, 78, 880-888.
125. Meck, W. H.; Smith, R. A.; Williams, C. L. Pre- and postnatal choline supplementation produces long-term facilitation of spatial memory. Dev. Psychobiol., 1988, 21, 339-353.
126. Papke, R. L.; Bencherif, M.; Lippiello, P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Neurosci. Lett., 1996, 213, 201-204.
127. Stevens, K. E.; Adams, C. E.; Mellott, T. J.; Robbins, E.; Kisley, M.A. Perinatal choline deficiency produces abnormal sensory inhibition in Sprague-Dawley rats. Brain Res., 2008, 1237, 84-90.
128. Stevens, K. E.; Adams, C. E.; Yonchek, J.; Hickel, C.; Danielson, J.; Kisley, M. A. Permanent improvement in deficient sensory inhibition in DBA/2 mice with increased perinatal choline. Psycho-pharmacology, 2008, (Berl) 198, 413-420.
129. Timmermann, D.B.; Gronlien, J. H.; Kohlhaas, K. L.; Nielsen, E. O.; Dam, E.; Jorgensen, T. D.; Ahring, P. K.; Peters, D.; Holst, D.; Chrsitensen, J. K.; Malysz, J.; Briggs, C. A.; Gopalakrishnan, M.; Olsen, G. M. An allosteric modulator of the alpha7 nicotinic ace-tylcholine receptor possessing cognition-enhancing properties in vivo. J. Pharmacol. Exp. Ther., 2007, 323, 294-307.
130. Nott, A.; Levin, E. D. Dorsal hippocampal alpha7 and alpha4beta2 nicotinic receptors and memory. Brain Res., 2006, 1081, 72-78.
131. Levin, E. D.; Bradley, A.; Addy, N.; Sigurani, N. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience, 2002, 109, 757-765.
132. Romanelli, M. N.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonac-cini, C.; Gualtieri, F. Central nicotinic receptors, structure, function, ligands, and therapeutic potential. ChemMedChem, 2007, 2, 746-767.
133. O'Neill, H. C.; Rieger, K.; Kem, W. R.; Stevens, K. E. DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology (Berl), 2003, 169, 332-339.
134. Kitagawa, H.; Takenouchi, T.; Azuma, R.; Wesnes, K. A.; Kramer, W. G.; Clody, D. E.; Burnett, A. L. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology, 2003, 28, 542-551.
135. Freedman, R.; Olincy, A.; Buchanan, R. W.; Harris, J. G.; Gold, J. M.; Johnson, L.; Allensworth, D.; Guzman-Bonilla, A.; Clement, B.; Ball, M. P.; Kutnick, J.; Pender, V.; Martin, L. F.; Stevens, K. E.; Wagner, B. D.; Zerbe, G. O.; Soti, F.; Kem, W. R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry., 2008, 165, 1040-1047.
136. Shiina, A.; Shirayama, Y.; Niitsu, T.; Hashimoto, T.; Yoshida, T.; Hasegawa, T.; Haraguchi, T.; Kanahara, N.; Shiraishi, T.; Fujisaki, M.; Fukami, G.; Nakazato, M.; Iyo, M.; Hashimoto, K. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann. Gen. Psychiatry, 2010, 9, 27.
137. Acker, B. A.; Jacobsen, E. J.; Rogers, B. N.; Wishka, D. G.; Reitz, S.C.; Piotrowski, D.W.; Myers, J. K.; Wolfe, M. L.; Groppi, V. E.; Thornburgh, B. A.; Tinholt, P. M.; Walters, R.; Olson, B. A.; Fitzgerald, L.; Staton, B. A.; Raub, T. J.; Krause, M.; Li, K. S.; Hoffmann, W. E.; Hajos, M.; Hurst, R. S.; Walker, D. P. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor, in vitro and in vivo activity. Bioorg. Med. Chem. Lett., 2008, 18, 3611-3615.
138. Levin, E. D.; Bettegowda, C.; Blosser, J.; Gordon, J. AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol., 1999, 10, 675-680.
139. Hurst, R. S.; Hajos, M.; Raggenbass, M.; Wall, T. M.; Higdon, N. R.; Lawson, J. A.; Rutherford-Root, K. L.; Berkenpas, M. B.; Hoffmann, W. E.; Piotrowski, D. W.; Groppi, V. E.; Allaman, G.; Ogier, R.; Bertrand, S.; Bertrand, D.; Arneric, S. P. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcho-line receptor, in vitro and in vivo characterization. J. Neurosci., 2005, 25, 4396-4405.
140. Singhal, S. K.; Zhang, L.; Morales, M.; Oz, M. Antipsychotic clo-zapine inhibits the function of alpha7-nicotinic acetylcholine receptors. Neuropharmacology, 2007, 52,387-394.
141. Grinevich, V. P.; Papke, R. L.; Lippiello, P. M.; Bencherif, M. Atypical antipsychotics as noncompetitive inhibitors of al-pha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharma-cology, 2009, 57, 183-191.
142. Yang, Y. K.; Nelson, L.; Kamaraju, L.; Wilson, W.; McEvoy, J. P. Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. Neuropsychopharmacology, 2002, 27, 684-686.
143. Pocivavsek, A.; Icenogle, L.; Levin, E. D. Ventral hippocampal alpha7 and alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in female rats. Psychopharmacology (Berl) 2006, 188, 597-604.
144. McEvoy, J. P.; Freudenreich, O.; Wilson, W. H. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol. Psychiatry, 1999, 46,125-129.
145. Xu, R.; Dwoskin, L. P.; Grinevich, V. P.; Deaciuc, G.; Crooks, P. A. Neuronal nicotinic acetylcholine receptor binding affinities of boron-containing nicotine analogues. Bioorg. Med. Chem. Lett., 2001, 11, 1245-1248.
146. Williams, J. M.; Ziedonis, D. M.; Abanyie, F.; Steinberg, M. L.; Foulds, J.; Benowitz, N. L. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr. Res., 2005, 79, 323-335.
147. Leonard, S.; Gault, J.; Moore, T.; Hopkins, J.; Robinson, M.; Olincy, A.; Adler, L. E.; Cloninger, C. R.; Kaufmann, C. A.; Tsu-ang, M. T.; Faraone, S. V.; Malaspina, D.; Svrakic, D. M.; Freed-man, R. Further investigation of a chromosome 15 locus in schizophrenia, analysis of affected sibpairs from the NIMH Genetics Initiative. Am. J. Med. Genet., 1998, 81, 308-312.
148. Riley, B. P.; Makoff, A.; Mogudi-Carter, M.; Jenkins, T.; Williamson, R.; Collier, D.; Murray R. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am. J. Med. Genet., 2000, 96,196-201.
149. Xu, J.; Pato, M. T.; Torre, C. D.; Medeiros, H.; Carvalho, C.; Basile, V. S.; Bauer, A.; Dourado, A.; Valente, J.; Soares, M. J.; Macedo, A. A.; Coelho, I.; Ferreira, C. P.; Azevedo, M. H.; Macci-ardi, F.; Kennedy, J. L.; Pato, C.N. Evidence for linkage disequilibrium between the alpha 7-nicotinic receptor gene (CHRNA7) locus and schizophrenia in Azorean families. Am. J. Med. Genet., 2001, 105, 669-674.
150. Liu, C. M.; Hwu, H. G.; Lin, M. W.; Ou-Yang, W. C.; Lee, S. F.; Fann, C. S.; Wong, S. H.; Hsieh, S. H.; Suggestive evidence for linkage of schizophrenia to markers at chromosome 15q13-14 in Taiwanese families. Am. J. Med. Genet., 2001, 105, 658-661.
151. Perl, O.; Ilani, T.; Strous, R. D.; Lapidus, R.; Fuchs, S. The alpha7 nicotinic acetylcholine receptor in schizophrenia, decreased mRNA levels in peripheral blood lymphocytes. FASEB J., 2003, 17, 1948-1950.
152. Perl, O.; Strous, R.D.; Dranikov, A.; Chen, R.; Fuchs, S. Low levels of alpha7-nicotinic acetylcholine receptor mRNA on peripheral blood lymphocytes in schizophrenia and its association with illness severity. Neuropsychobiology, 2006, 53, 88-93.